AU2020267165B2 - Combination treatment - Google Patents

Combination treatment Download PDF

Info

Publication number
AU2020267165B2
AU2020267165B2 AU2020267165A AU2020267165A AU2020267165B2 AU 2020267165 B2 AU2020267165 B2 AU 2020267165B2 AU 2020267165 A AU2020267165 A AU 2020267165A AU 2020267165 A AU2020267165 A AU 2020267165A AU 2020267165 B2 AU2020267165 B2 AU 2020267165B2
Authority
AU
Australia
Prior art keywords
ticagrelor
protein
recombinant
patient
apyrase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020267165A
Other languages
English (en)
Other versions
AU2020267165A1 (en
Inventor
Lina Badimon
Leif Carlsson
Ola Fjellstrom
Sven NYLANDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2020267165A1 publication Critical patent/AU2020267165A1/en
Application granted granted Critical
Publication of AU2020267165B2 publication Critical patent/AU2020267165B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020267165A 2020-08-19 2020-11-10 Combination treatment Active AU2020267165B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063067388P 2020-08-19 2020-08-19
US63/067,388 2020-08-19

Publications (2)

Publication Number Publication Date
AU2020267165A1 AU2020267165A1 (en) 2022-03-10
AU2020267165B2 true AU2020267165B2 (en) 2024-01-04

Family

ID=77666491

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020267165A Active AU2020267165B2 (en) 2020-08-19 2020-11-10 Combination treatment

Country Status (9)

Country Link
US (2) US20220073888A1 (enExample)
EP (1) EP4199955A1 (enExample)
JP (1) JP7657041B2 (enExample)
KR (1) KR20220022828A (enExample)
CN (1) CN116096874A (enExample)
AU (1) AU2020267165B2 (enExample)
CA (1) CA3098818A1 (enExample)
TW (1) TW202207937A (enExample)
WO (1) WO2022038191A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg
KR20260113060A (ko) * 2023-11-16 2026-07-21 하이로리스 디벨롭먼츠 에스에이 피부경유 관상동맥 중재술 (pci)을 겪은 환자에서 허혈성 사건의 치료, 감소 또는 예방에 사용을 위한 티카그렐러 iv
WO2025104274A1 (en) * 2023-11-16 2025-05-22 Hyloris Developments Sa Ticagrelor iv for use in the prevention of thromboembolic events

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088231A1 (en) * 2010-01-13 2011-07-21 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP2133430B1 (en) 2004-02-27 2014-12-17 APT Therapeutics, Inc. Design and therapeutic use of adpase enhanced apyrases
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
BR112012017243A2 (pt) 2010-01-13 2017-09-19 Apt Therapeutics Inc constructos terapêuticos de apirase, agentes de apirase, e métodos de produção
RS66536B1 (sr) 2016-04-21 2025-03-31 Astrazeneca Ab Tablete za oralno raspadanje

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088231A1 (en) * 2010-01-13 2011-07-21 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D. MOECKEL ET AL: "Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk", SCIENCE TRANSLATIONAL MEDICINE, vol. 6, no. 248, 6 August 2014 (2014-08-06), pages 248ra105 - 248ra105 *

Also Published As

Publication number Publication date
JP7657041B2 (ja) 2025-04-04
WO2022038191A1 (en) 2022-02-24
US20220073888A1 (en) 2022-03-10
US12668785B2 (en) 2026-06-30
CN116096874A (zh) 2023-05-09
US20240026318A1 (en) 2024-01-25
EP4199955A1 (en) 2023-06-28
CA3098818A1 (en) 2022-02-19
AU2020267165A1 (en) 2022-03-10
KR20220022828A (ko) 2022-02-28
TW202207937A (zh) 2022-03-01
JP2022035920A (ja) 2022-03-04

Similar Documents

Publication Publication Date Title
US20240026318A1 (en) Combination treatment
Ogawa et al. Antithrombotic Therapy in Atrial Fibrillation–Evaluation and Positioning of New Oral Anticoagulant Agents–
Broussalis et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies
White Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions
Schulz et al. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo
US20240000744A1 (en) Treatment of Hemophilia with Fitusiran
AU2023281591A1 (en) Treatment method using mazdutide
US20230139826A1 (en) Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion
US20250268902A1 (en) Therapeutic methods
JP2019507174A (ja) 心血管疾患におけるリラグルチド
CN106488773B (zh) Apc类似物用于创伤愈合的用途
Ohno et al. Repetitive stent thrombosis in a patient who had resistance to both clopidogrel and prasugrel
Yalcin-Cakmakli et al. Right internal carotid artery occlusion during intravenous thrombolysis for left middle cerebral artery occlusion
EP4608433A1 (en) Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg
TW202342065A (zh) 治療血友病的方法和組成物
EP2501399A2 (en) Treatment of acute ischemic stroke or intracranial bleeding with tpa and carbamylated erythropoietin
EP2445505B1 (en) Combined use of creatine phosphate and creatine phosphokinase for treatment of arteriosclerosis
Gibler et al. Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting
Willis et al. Streptokinase-induced subcapsular hematoma of the liver
Schwartz et al. Use of antiplatelet agents to prevent stroke: What is the role for combinations of medications?
Rakhit Case 2: patent foramen ovale (PFO) and paradoxical embolism
Suzuki et al. Hypertensive crisis and left ventricular thrombi after an upper respiratory infection during the long-term use of oral contraceptives
FRENCH STEMI–a medical emergency
Dulsat European Society of Cardiology (ESC) Congress 2019. Paris, France-August 31-September 4, 2019
TW200835509A (en) Administration of enoxaparin sodium to patients with acute ischemic stroke

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)